Circulating S100 proteins effectively discriminate SLE patients
from healthy controls: a cross-sectional study

J 2019

Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study

ŠUMOVÁ, Barbora, Lucie Andrés CEREZO, Lenka SZCZUKOVÁ, Lucie NEKVINDOVÁ, Michal UHER et. al.

Základní údaje

Originální název

Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study

Autoři

ŠUMOVÁ, Barbora (203 Česká republika), Lucie Andrés CEREZO (203 Česká republika), Lenka SZCZUKOVÁ (203 Česká republika, domácí), Lucie NEKVINDOVÁ (203 Česká republika, domácí), Michal UHER (203 Česká republika, domácí), Hana HULEJOVÁ (203 Česká republika), Radka MORAVCOVÁ (203 Česká republika), Mariam GRIGORIAN (208 Dánsko), Karel PAVELKA (203 Česká republika), Jiří VENCOVSKÝ (203 Česká republika), Ladislav ŠENOLT (203 Česká republika) a Jakub ZÁVADA (203 Česká republika, garant)

Vydání

Rheumatology International, Heidelberg, Springer, 2019, 0172-8172

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30226 Rheumatology

Stát vydavatele

Německo

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 1.984

Kód RIV

RIV/00216224:14110/19:00109000

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1007/s00296-018-4190-2

UT WoS

000458566100007

Klíčová slova anglicky

Biomarkers; SLE; S100 proteins; Disease activity

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 15. 4. 2019 14:50, Soňa Böhmová

Anotace

V originále

S100 proteins are currently being investigated as potential diagnostic and prognostic biomarkers of several cancers and inflammatory diseases. The aims of this study were to analyse the plasma levels of S100A4, S100A8/9 and S100A12 in patients with incomplete systemic lupus erythematosus (iSLE), in patients with established SLE and in healthy controls (HCs) and to investigate the potential utility of the S100 proteins as diagnostic or activity-specific biomarkers in SLE. Plasma levels were measured by ELISA in a cross-sectional cohort study of 44 patients with SLE, 8 patients with iSLE and 43 HCs. Disease activity was assessed using the SLEDAI-2K. The mean levels of all S100 proteins were significantly higher in SLE patients compared to HCs. In iSLE patients, the levels of S100A4 and S100A12 but not S100A8/9 were also significantly higher compared to HCs. There were no significant differences in S100 levels between the iSLE and SLE patients. Plasma S100 proteins levels effectively discriminated between SLE patients and HCs. The area under the curve (AUC) for S100A4, S100A8/9 and S100A12 plasma levels was 0.989 (95% CI 0.976-1.000), 0.678 (95% CI 0.563-0.792) and 0.807 (95% CI 0.715-0.899), respectively. S100 levels did not differentiate between patients with high and low disease activity. Only the S100A12 levels were significantly associated with SLEDAI-2K and with cSLEDAI-2K. S100 proteins were significantly higher in SLE patients compared HCs and particularly S100A4 could be proposed as a potential diagnostic biomarker for SLE.

Citovat

ŠUMOVÁ, Barbora, Lucie Andrés CEREZO, Lenka SZCZUKOVÁ, Lucie NEKVINDOVÁ, Michal UHER, Hana HULEJOVÁ, Radka MORAVCOVÁ, Mariam GRIGORIAN, Karel PAVELKA, Jiří VENCOVSKÝ, Ladislav ŠENOLT a Jakub ZÁVADA. Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study. Rheumatology International. Heidelberg: Springer, 2019, roč. 39, č. 3, s. 469-478. ISSN 0172-8172. Dostupné z: https://dx.doi.org/10.1007/s00296-018-4190-2.

@article{1486400,
   author = {Šumová, Barbora and Cerezo, Lucie Andrés and Szczuková, Lenka and Nekvindová, Lucie and Uher, Michal and Hulejová, Hana and Moravcová, Radka and Grigorian, Mariam and Pavelka, Karel and Vencovský, Jiří and Šenolt, Ladislav and Závada, Jakub},
   article_location = {Heidelberg},
   article_number = {3},
   doi = {http://dx.doi.org/10.1007/s00296-018-4190-2},
   keywords = {Biomarkers; SLE; S100 proteins; Disease activity},
   language = {eng},
   issn = {0172-8172},
   journal = {Rheumatology International},
   title = {Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study},
   url = {http://dx.doi.org/10.1007/s00296-018-4190-2},
   volume = {39},
   year = {2019}
}

TY  - JOUR
ID  - 1486400
AU  - Šumová, Barbora - Cerezo, Lucie Andrés - Szczuková, Lenka - Nekvindová, Lucie - Uher, Michal - Hulejová, Hana - Moravcová, Radka - Grigorian, Mariam - Pavelka, Karel - Vencovský, Jiří - Šenolt, Ladislav - Závada, Jakub
PY  - 2019
TI  - Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study
JF  - Rheumatology International
VL  - 39
IS  - 3
SP  - 469-478
EP  - 469-478
PB  - Springer
SN  - 01728172
KW  - Biomarkers
KW  - SLE
KW  - S100 proteins
KW  - Disease activity
UR  - http://dx.doi.org/10.1007/s00296-018-4190-2
L2  - http://dx.doi.org/10.1007/s00296-018-4190-2
N2  - S100 proteins are currently being investigated as potential diagnostic and prognostic biomarkers of several cancers and inflammatory diseases. The aims of this study were to analyse the plasma levels of S100A4, S100A8/9 and S100A12 in patients with incomplete systemic lupus erythematosus (iSLE), in patients with established SLE and in healthy controls (HCs) and to investigate the potential utility of the S100 proteins as diagnostic or activity-specific biomarkers in SLE. Plasma levels were measured by ELISA in a cross-sectional cohort study of 44 patients with SLE, 8 patients with iSLE and 43 HCs. Disease activity was assessed using the SLEDAI-2K. The mean levels of all S100 proteins were significantly higher in SLE patients compared to HCs. In iSLE patients, the levels of S100A4 and S100A12 but not S100A8/9 were also significantly higher compared to HCs. There were no significant differences in S100 levels between the iSLE and SLE patients. Plasma S100 proteins levels effectively discriminated between SLE patients and HCs. The area under the curve (AUC) for S100A4, S100A8/9 and S100A12 plasma levels was 0.989 (95% CI 0.976-1.000), 0.678 (95% CI 0.563-0.792) and 0.807 (95% CI 0.715-0.899), respectively. S100 levels did not differentiate between patients with high and low disease activity. Only the S100A12 levels were significantly associated with SLEDAI-2K and with cSLEDAI-2K. S100 proteins were significantly higher in SLE patients compared HCs and particularly S100A4 could be proposed as a potential diagnostic biomarker for SLE.
ER  -

ŠUMOVÁ, Barbora, Lucie Andrés CEREZO, Lenka SZCZUKOVÁ, Lucie NEKVINDOVÁ, Michal UHER, Hana HULEJOVÁ, Radka MORAVCOVÁ, Mariam GRIGORIAN, Karel PAVELKA, Jiří VENCOVSKÝ, Ladislav ŠENOLT a Jakub ZÁVADA. Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study. \textit{Rheumatology International}. Heidelberg: Springer, 2019, roč.~39, č.~3, s.~469-478. ISSN~0172-8172. Dostupné z: https://dx.doi.org/10.1007/s00296-018-4190-2.

Podrobný výpis o publikaci